Business Advisory Board
General Partner at Advent Life Sciences
Dale joined Advent in 2010 and has 25 years of experience as a life science entrepreneur and executive.
His area of expertise lies in high technology research tools, genomics, diagnostics and therapeutics. Dale’s first company, founded while he was in graduate school, was acquired by SmithKline Beckman. Since then, he has steered many companies to success.
Early in his career, he was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE). As founding CEO and Chairman of Orchid BioSciences, a pioneer in genetic analysis and personalised medicine, Dale and his team built the company through strategic acquisitions and took it public in 2000. (NASDAQ: ORCH).
Later, he was founding CEO and Chairman of Acuity Pharmaceuticals, an innovative ophthalmology company acquired by OPKO Health (NYSE AMEX: OPK) and as CEO of Receptor BioLogix, the cancer drug developer, he prepared the company for acquisition by a European biotechnology firm.
Dale holds a BS degree from the University of California and a PhD in Physics from Brown University.